AbTLAS
- Biotech or pharma, therapeutic R&D
AbTLAS is a spin-off company from Scripps Korea Antibody Institute, established by Scripps Research Institute, Kangwon state, Chuncheon City, and Kangwon National University. AbTLAS has FAST platform, a transformative antibody discovery technology that would lead to a new horizon in antibody therapeutics through unlimited antibody discovery. Unlike current antibody discovery, FAST platform uses spatially addressed antibody library, enabling high throughput screening of individual antibodies based on biological functions (patented). Thus, FAST platform makes it possible to discover innovative antibodies against challenging targets including GPCRs, and phenotypic antibodies for diseases without treatments or known drug targets. With highly scalable FAST platform, AbTLAS is prepared to take on many discovery projects and partnership discovery is available for biotech and pharmaceutical companies that strive to develop innovative antibodies for challenging targets and diseases.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}